This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

March 18, 2021
Delivered DigitallyCentral European Time

Amaro Therapeutics, Inc.


Amaro Therapeutics is building the preeminent biotechnology company around man's first 'therapeutic' targets - taste receptors - to develop therapies for the treatment of metabolic and immunologic diseases and conditions. We are exploiting an endogenous system, predominately designed as a defensive barrier to toxins and noxious substances, to produce a series of systemic- and tissue-specific biological responses which we believe can modulate immune-metabolic pathologies sufficient to return a patient to homeostasis.  We expect that our discovery platform will identify multiple indications for which taste receptor modulation, at the systemic and tissue level, creates potent complimentary and synergistic biological effects.  We believe the breadth of indications treatable through taste receptor modulation is broad and encompasses both niche patient populations such as polycystic ovary syndrome as well as large heterogenic diseases such as diabetes, obesity, and NASH.  Research further suggests that modulation of taste receptors impacts both longevity and the gut-brain axis.